Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Urinary Tract Calculi III: Medical Management01:30

Urinary Tract Calculi III: Medical Management

The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Urinary Tract Calculi IV: Nutrition Therapy and Prevention01:27

Urinary Tract Calculi IV: Nutrition Therapy and Prevention

Management of renal calculi focuses on effective strategies like tailored nutrition and hydration therapy. Adjusting diet and fluid intake reduces stone formation and recurrence, making these interventions simple yet powerful in kidney stone prevention and management.Understanding Kidney StonesKidney stones form when calcium, oxalate, uric acid, and cystine concentrate and crystallize in urine. Factors contributing to their formation include genetic predisposition, certain medical conditions,...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ADAR1 loss-of-function variants altering RNA editing define a new interferon-dependent psoriasis subtype.

The Journal of experimental medicine·2026
Same author

Diagnostic accuracy of <sup>18</sup>F-FDG PET-CT scores in distinguishing polymyalgia rheumatica from other inflammatory rheumatic diseases: a multicentre retrospective study (RHUMATEP).

European journal of nuclear medicine and molecular imaging·2026
Same author

900 patients evaluated within a median of 1 day from referral in a very early arthritis clinic in France.

Rheumatology advances in practice·2026
Same author

Club Rhumatismes et Inflammation guidelines for anti-interleukin-1 therapy: 2026 update.

Joint bone spine·2026
Same author

Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions for disease elements in calcium pyrophosphate crystal deposition (CPPD).

Annals of the rheumatic diseases·2026
Same author

Relapse risk of lupus-related serositis according to immunosuppressive therapy: a national real-world study.

RMD open·2026

Related Experiment Video

Updated: May 31, 2026

Tuina Intervention in Sodium Monoiodoacetate Injection-Induced Rat Model of Knee Osteoarthritis
06:14

Tuina Intervention in Sodium Monoiodoacetate Injection-Induced Rat Model of Knee Osteoarthritis

Published on: January 12, 2024

[New therapeutic options for gout].

Pascal Richette1, Sébastien Ottaviani, Thomas Bardin

  • 1Université Paris 7, Assistance-publique-Hôpitaux de Paris, hôpital Lariboisière, fédération de rhumatologie, UFR médicale, 2, rue Ambroise-Paré, 75475 Paris Cedex 10, France. pascal.richette@lrb.aphp.fr

Presse Medicale (Paris, France : 1983)
|June 21, 2011
PubMed
Summary

New gout medications offer hope for managing chronic hyperuricemia and acute arthritis, especially in patients with kidney or cardiovascular issues. Novel drugs like Febuxostat and biologics targeting interleukin-1 beta show promise.

Related Experiment Videos

Last Updated: May 31, 2026

Tuina Intervention in Sodium Monoiodoacetate Injection-Induced Rat Model of Knee Osteoarthritis
06:14

Tuina Intervention in Sodium Monoiodoacetate Injection-Induced Rat Model of Knee Osteoarthritis

Published on: January 12, 2024

Area of Science:

  • Rheumatology
  • Pharmacology

Background:

  • Gout management is challenging for patients with renal failure or cardiovascular conditions.
  • Chronic hyperuricemia and acute arthritis necessitate advanced therapeutic strategies.
  • Urate deposition in severe gout requires effective hypouricemic agents.

Purpose of the Study:

  • To review emerging and recently approved drugs for managing chronic hyperuricemia and acute gouty arthritis.
  • To highlight novel therapeutic approaches for difficult-to-treat gout cases.
  • To discuss the role of new pharmacological agents in addressing unmet needs in gout treatment.

Main Methods:

  • Review of recently approved and investigational drugs for gout.
  • Discussion of Febuxostat's mechanism as a selective xanthine oxidase inhibitor.
  • Exploration of biologic agents targeting interleukin-1 beta for acute gout attacks.

Main Results:

  • Febuxostat, a novel xanthine oxidase inhibitor, is approved for chronic hyperuricemia, with no dose adjustment needed for mild-to-moderate renal impairment.
  • Pegloticase (PEG-uricase) and RDEA594 represent other novel hypouricemic and uricosuric drug developments.
  • Interleukin-1 beta inhibitors (canakinumab, rilonacept, anakinra) show promising efficacy in treating acute gouty arthritis.

Conclusions:

  • Emerging drugs like Febuxostat, pegloticase, and IL-1 beta inhibitors offer new avenues for gout management.
  • These novel therapies address challenges in patients with comorbidities, improving treatment outcomes.
  • Continued research and development in hypouricemic and anti-inflammatory agents are crucial for advancing gout care.